Adding Novel ADC Candidate to Oncology Pipeline

Chong Kun Dang Pharm Licenses Synaffix ADC Technology

2023/02/06

Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies. Single-target license with upfront and milestone payments plus royalties. First Synaffix partnership announced with a Korean company.

Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Chong Kun Dang Pharm (CKD), a global pharmaceutical company based in South Korea, today announce that they have entered a licensing agreement.

The agreement provides CKD a license for global, target-specific rights to Synaffix’s proprietary ADC technology, adding a new ADC drug candidate to CKD’s pipeline. CKD will have access to Synaffix’s ADC technologies, comprising GlycoConnect™, HydraSpace™ and an undisclosed linker-payload from the toxSYN™ platform. Under the terms of the agreement, Synaffix has received an upfront payment and is eligible to receive further milestone payments plus royalties on commercial sales. CKD will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.

Scientific rigor and a growing body of promising underlying data have led us to this exciting moment where we can bring a new ADC into the development pipeline of CKD Pharm.

Peter van de Sande, Chief Executive Officer of Synaffix